All In Biotech

Drug Trial Radar · NCT04227990

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

Last checked: Nov 19, 2026Latest source record: Jan 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

115

Actual

Start

Nov 27, 2017

Primary completion

Oct 15, 2018

Study completion Jan 3, 2019

Sponsor

Sponsor type
Industry
First posted
Jan 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to compare the duration of severe neutropenia (DSN) in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and cyclophosphamide (TAC) + monotheray plinabulin or combination plinabulin/pegfilgrastim Severe neutropenia is an absolute neutrophil count (ANC) \<0.5 × 10\^9/L. Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study.

Conditions

  • Chemotherapy-induced Neutropenia

Interventions

  • PlinabulinDrug

    Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

  • PegfilgrastimDrug

    Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

  • Docetaxel, doxorubicin, and cyclophosphamide (TAC)Drug

    Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Severe Neutropenia (DSN)Time frame: Cycle 1 (21 days)

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Cancer Center of Guangzhou Medical University Breast Oncology

    Guangzhou, Guangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, Harbin, China

  • Fourth Hospital of Hebei Medical University Breast cancer department

    Shijiazhuang, Hebei, China

  • China-Japan Union Hospital of Jilin University Tumor department of Hematology

    Changchun, Jilin, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Shenyang, China

  • Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department

    Dnipro, Ukraine

  • Prykarpatskiy Regional Oncological Center

    Ivano-Frankivsk, Ukraine

  • "V.T. Zaycev Institute of General and Urgent Surgery NAMS of Ukraine Dept. of Oncology

    Kharkiv, Ukraine

  • Kirovograd Regional Oncological Center

    Kropyvnytskyi, Ukraine

  • Public Institution Kryvyi Rih Oncology Center

    Krutyi Bereh, Ukraine

  • Odessa regional clinical hospital Thoracic Surgery Department Academician Zabolotnoho

    Odesa, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.